Core Viewpoint - The company, Da Dongfang (600327.SH), is expected to report a significant net loss for the fiscal year 2025, with projections indicating a loss between 235 million to 175 million yuan, compared to the previous year [1] Financial Performance - The anticipated net profit attributable to the parent company for 2025 is projected to be between -235 million yuan and -175 million yuan, indicating a loss compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between -215 million yuan and -155 million yuan [1] Business Segments - The department store business is focusing on enhancing招商力度 (recruitment efforts), strengthening advantageous categories, optimizing consumer scenarios, upgrading customer experience, and enhancing holiday marketing and membership management [1] - Despite efforts in the department store segment, revenue and gross profit have slightly declined due to a downturn in consumer spending and the impact of traditional supermarket channels [1] - The pediatric medical business is concentrating on developing existing business while actively expanding into new disciplines and products, improving the quality of medical services [1] - Although revenue in the pediatric medical segment has decreased, gross profit has increased, leading to a year-on-year profit growth, indicating stable operations in the main business [1]

南财智讯1月29日电，创新医疗发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3300万元—-2600万元，同比预增64.88%—72.33%；预计2025年全年归属于上市公司股东的扣除非经 常性损益的净利润为-7500万元—-6800万元，同比预减14.14%—25.89%。业绩变动原因说明：1、本报 告期归属于上市公司股东的净利润出现同比上升，主要系：公司增持博灵脑机股权并将该公司纳入合并 报表范围，根据《企业会计准则第33号——合并财务报表》第四十八条的规定，确认了相应的投资收 益；李晔案件再审改判后，建华医院收到了法院返还的被执行款项，并由此确认了营业外收入。2、本 报告期扣除非经常性损益后的净利润出现同比下降，主要系：在医保政策以及医保支付标准持续调整的 行业背景下，康华医院、建华医院对短期盈利预期的不确定性进行了审慎评估，本报告期确认的递延所 得税资产同比减少，导致所得税费用出现同比上升。 ...

煤炭业务板块亏损因素：(1)安佳矿业2025年受生产系统设备改造、瓦斯治理工程施工、区域性安全管 理等因素影响有效开采时间，致原煤产量偏低，综合成本偏高。(2)煤炭销售单价下降。(3)根据《企业 会计准则》及公司会计政策的相关规定，基于会计谨慎性原则，审慎反映资产质量，对存在减值迹象的 长期资产进行减值测试，预计计提减值准备。 智通财经APP讯，赤天化(600227.SH)发布2025年年度业绩预亏公告，预计2025年年度实现归属于母公 司所有者净亏损2.8亿元至3.8亿元，与上年同期(法定披露数据)相比，将出现连续亏损。 医疗服务业务板块亏损因素：公司旗下医院尚处于发展初期，虽然营业收入较上年同期增长约60%，但 营业收入中药品、耗材收入占比较大，药品、耗材无利润，导致医院毛利较低，加之仍处于市场、口碑 培育期，人力成本、折旧等固定成本摊销较高等因素，致医院仍处于亏损阶段。 化工业务板块：因2025年停产大修致产量减少，收入减少，大修费用增加，导致桐梓化工净利润同比上 期减少。 ...

创新医疗公告，预计2025年度净利润为负值，归属于上市公司股东的净利润预计在-3300万元至-2600万 元之间，上年同期为-9395.4万元，比上年同期增长64.88%～72.33%。扣除非经常性损益后的净利润预 计在-7500万元至-6800万元之间，上年同期为-5957.41万元，比上年同期下降14.14%～25.89%。营业收 入预计在7.8亿元至8亿元之间，上年同期为8.16亿元。 ...

Core Insights - The medical services sector experienced a rise of 1.61% on January 29, with Tongce Medical leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Services Sector Performance - Tongce Medical (600763) closed at 47.49, with a gain of 5.14%, and a trading volume of 206,500 shares, amounting to a transaction value of 9.65 billion [1] - Other notable performers included: - Digital Human (920670) at 20.26, up 3.90%, with a transaction value of 2.08 billion [1] - Meinian Health (002044) at 7.28, up 3.70%, with a transaction value of 24.68 billion [1] - Tiger Medical (300347) at 58.91, up 3.51%, with a transaction value of 7.82 billion [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.146 billion from institutional investors, while retail investors experienced a net outflow of 1.043 billion [2][3] - Key stocks with significant capital flow included: - WuXi AppTec (603259) with a net inflow of 306 million, representing 5.87% of total capital [3] - Aier Eye Hospital (300015) with a net inflow of 228 million, representing 15.83% of total capital [3] - Meinian Health (002044) with a net inflow of 163 million, representing 6.60% of total capital [3]

（记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，港通医疗1月29日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损200 万元~400万元，同比由盈转亏。业绩变动主要原因是：报告期内，公司主要合同执行进度不及预期， 公司营业收入有所下降。公司客户主要系公立医院、国资公司等单位，受财政资金、审计结算周期等影 响，公司回款周期加长，应收账款增加，应收账款减值准备计提有所增加。受金融市场利率持续下降影 响，理财收益有所下降；新投资子公司尚处于初创、培育阶段，尚未形成规模收入，费用有所增加；导 致年度内期间费用有所上升。未来，公司将积极采取措施，加大市场开拓力度，提升营业规模；增加成 本费用控制手段，提升经营利润；加大货款催收力度，提升应收账款周转率；努力提升公司综合竞争 力，改善经营业绩。 每日经济新闻 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 ...

Core Viewpoint - The company, Tigermed (300347.SZ), expects a significant increase in net profit attributable to shareholders for 2025, projecting between 830 million to 1.23 billion RMB, representing a growth of 105% to 204% compared to the previous year [1] Financial Performance - The increase in profit is primarily due to a substantial rise in non-recurring gains and losses during the reporting period [1] - The company has seen a notable improvement in the disposal and holding gains of its non-current financial assets, which include equity stakes in non-listed companies, shares in listed companies, and pharmaceutical funds [1] Industry Context - The recovery of the Chinese innovative drug industry has contributed to the restoration of asset values [1] - The company has achieved good growth in both the number and value of new orders compared to the same period last year [1] Order Growth - For 2025, the company anticipates net new orders (newly signed orders minus canceled orders) to be in the range of 9.5 billion to 10.5 billion RMB, compared to 8.42 billion RMB in net new orders for the same period in 2024 [1]

泰格医药(300347.SZ)公告称，预计2025年归属于上市公司股东的净利润为8.30亿元–12.30亿元，比上年 同期增长105%–204%。业绩变动主要系报告期内非经常性损益大幅增加，公司持有的非流动金融资产 （包括非上市公司股权、上市公司股份及医药基金）处置及持有收益显著提升，叠加中国 创新药行业 复苏带动资产价值修复。公司的新签订单数量和金额均较去年同期实现较好增长。2025年，公司净新增 订单（新签订单剔除取消订单后）区间为人民币95亿元至人民币105亿元，2024年同期净新增订单为人 民币84.20亿元。 ...

Core Viewpoint - The company, Saili Medical, anticipates a net loss attributable to shareholders of between -160 million RMB and -209 million RMB for the fiscal year 2025, indicating a reduction in losses compared to the previous year [1] Group 1: Financial Performance - The expected net loss for 2025 represents a decrease in losses by 49.2397 million RMB to 2.397 million RMB year-on-year [1] - The primary reason for the performance change is a decline in operating revenue [1] Group 2: Strategic Changes - The company is undergoing a strategic transformation, which includes the transfer of part of its controlling subsidiaries, resulting in these subsidiaries no longer being included in the consolidated financial statements [1] - The decision to not renew certain business contracts after their expiration has also contributed to the decline in operating revenue [1] Group 3: Research and Development - The company is increasing its investment in research and development within the smart medical field, which is impacting profitability due to higher R&D expenses [1]

塞力医疗公告称，预计2025年度归属于上市公司股东的净利润为-1.6亿元到-2.09亿元，同比亏损减少 0.24亿-0.49亿元；扣非净利润为-1.8亿元到-2.3亿元，同比亏损增加0.45亿-0.95亿元。上年同期净利润 为-2.09亿元。业绩预亏主因是转让部分控股子公司、业务到期未续约及行业政策影响致营收下降，研 发投入增加，以及应收债权和商誉减值。目前商誉等资产价值评估结果未确定，最终财务数据以2025年 年报为准。 ...